IMVT

Immunovant, Inc. - Common Stock (IMVT)

About Immunovant, Inc. - Common Stock (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Details

Daily high
$17.92
Daily low
$17.41
Price at open
--
52 Week High
$34.47
52 Week Low
$12.72
Market cap
3.0B
Dividend yield
0.00%
Volume
1
Avg. volume
1.3M
P/E ratio
-6.51

Immunovant, Inc. - Common Stock News

Details

Daily high
$17.92
Daily low
$17.41
Price at open
--
52 Week High
$34.47
52 Week Low
$12.72
Market cap
3.0B
Dividend yield
0.00%
Volume
1
Avg. volume
1.3M
P/E ratio
-6.51